top of page

Recordati to acquire EUSA Pharma for €750m, gaining 4 rare cancer drugs

Italian drugmaker Recordati has agreed on a price for six-year-old EUSA Pharma. The Milan-based firm will pay €750m ($845 million) for EUSA’s portfolio of drugs to treat rare cancers.


U.K.-based EUSA, which employs 200 people around the world, has developed four products, including an antibody treatment for children with neuroblastoma. A potential FDA approval for the treatment, known commercially as Qurziba, could bump annual sales of EUSA’s products from €130 million ($147 million) to €250 million ($282 million), Recordati said in a Friday release.


Another promising product Recordati acquires in the deal is Caphosol, an FDA-approved medical device to counter some side effects from chemotherapy and radiotherapy. Also included is Sylvant, an approved antibody for idiopathic multicentric Castleman’s disease, and Fotivda, an oral treatment for advanced renal cell carcinoma.




Comments


bottom of page